Acquiring Company
Processa Pharmaceuticals
Acquired Company
Vidya Therapeutics
HanoverHealthcareBiotechnologyHealth CareDescription
Processa Pharmaceuticals has announced the acquisition of Vidya Therapeutics in an all-stock transaction. This acquisition will bring Vidya's BTK inhibitor drug into Processa's pipeline, aiming to address various immune-mediated disorders. The deal also includes a $200 million private placement to support further drug development. The transaction is expected to close shortly, shifting significant stock ownership within Processa.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Vidya Therapeutics?
Vidya Therapeutics was acquired by Processa Pharmaceuticals, based in Hanover. The deal was reported on July 29, 2026. Processa Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with unmet medical needs. Processa Pharmaceuticals is publicly traded (PCSA) and operates in Healthcare.
When did Processa Pharmaceuticals acquire Vidya Therapeutics?
Processa Pharmaceuticals's acquisition of Vidya Therapeutics was reported on July 29, 2026. Processa Pharmaceuticals has announced the acquisition of Vidya Therapeutics in an all-stock transaction. This acquisition will bring Vidya's BTK inhibitor drug into Processa's pipeline, aiming to address various immune-mediated disorders. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Vidya Therapeutics do?
Vidya Therapeutics is a clinical-stage biotech company developing innovative drugs targeted towards immune-mediated disorders. Its main asset includes a novel BTK inhibitor designed for various applications in immunology. It is privately held, operating in Biotechnology.